We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Cronos Group (CRON - Free Report) closed the most recent trading day at $10.94, moving -1.89% from the previous trading session. The stock lagged the S&P 500's daily gain of 0.28%. At the same time, the Dow added 0.21%, and the tech-heavy Nasdaq gained 0.65%.
Heading into today, shares of the cannabis company had lost 12.64% over the past month, lagging the Finance sector's loss of 0.56% and the S&P 500's gain of 0.86% in that time.
Investors will be hoping for strength from CRON as it approaches its next earnings release, which is expected to be November 26, 2018. The company is expected to report EPS of $0.01, unchanged from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $11.29 million, up 975.24% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.02 per share and revenue of $23.87 million, which would represent changes of -300% and +649.69%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for CRON. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. CRON is currently a Zacks Rank #3 (Hold).
The Financial - Investment Management industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 116, which puts it in the top 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know
Cronos Group (CRON - Free Report) closed the most recent trading day at $10.94, moving -1.89% from the previous trading session. The stock lagged the S&P 500's daily gain of 0.28%. At the same time, the Dow added 0.21%, and the tech-heavy Nasdaq gained 0.65%.
Heading into today, shares of the cannabis company had lost 12.64% over the past month, lagging the Finance sector's loss of 0.56% and the S&P 500's gain of 0.86% in that time.
Investors will be hoping for strength from CRON as it approaches its next earnings release, which is expected to be November 26, 2018. The company is expected to report EPS of $0.01, unchanged from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $11.29 million, up 975.24% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.02 per share and revenue of $23.87 million, which would represent changes of -300% and +649.69%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for CRON. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. CRON is currently a Zacks Rank #3 (Hold).
The Financial - Investment Management industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 116, which puts it in the top 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.